COVID-19, heavy drinking and alcohol use disorders: a national study of Veterans Administration patients
COVID-19、酗酒和酒精使用障碍:一项针对退伍军人管理局患者的全国研究
基本信息
- 批准号:10371482
- 负责人:
- 金额:$ 25.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAcute Respiratory Distress SyndromeAddressAffectAgeAlcohol consumptionAlcoholsBehavioralBig DataBiologicalBlack PopulationsBlack raceCOVID-19COVID-19 prognosisCOVID-19 riskCOVID-19 severityCOVID-19 susceptibilityCOVID-19 vaccinationCaringCause of DeathCessation of lifeCharacteristicsChronicComputerized Medical RecordCountyDataDatabasesDiabetes MellitusDiagnosisDiagnosticDisastersEthnic OriginEventExploratory/Developmental GrantFundingFutureGeneral PopulationHealthHealth behaviorHeavy DrinkingHispanicHispanic PopulationsHospitalizationHypertensionICD-10-CMImmune responseImmune systemImpairmentIndividualInfectionIntensive CareKnowledgeLinkLogistic RegressionsMedicalMedicareMinorityMisinformationModelingNational Institute on Alcohol Abuse and AlcoholismObesityOutcomePatientsPersonsPneumoniaPoliciesPovertyPrevalencePreventiveProcessPrognosisProviderRaceResearch InfrastructureRetrospective cohortRiskSARS-CoV-2 exposureSARS-CoV-2 infectionSARS-CoV-2 negativeScientistServicesSocial EnvironmentStatistical Data InterpretationStressSystemTestingTimeUnited States Department of Veterans AffairsVaccinatedVaccinationVaccinesVeteransVirus DiseasesVital Statusalcohol effectalcohol use disordercoronavirus diseasecostdata repositorydata resourcedata sharingdata sharing networksdemographicsdesigndrinkinghousing instabilityhuman old age (65+)indexinginfection riskinterestmalemenmortalitynovel coronaviruspandemic diseaseresidencescreeningservice providerssexsociodemographicsvaccine distribution
项目摘要
Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2 is a global pandemic. While most COVID-19
cases are mild or moderate, severe cases (~15%) require hospitalization, critical cases (~5%) require intensive
care, and many deaths occur. Males, Blacks and Hispanics are at greater risk for COVID-19 infection, and poor
prognosis is predicted by older age, race/ethnicity, and prior underlying medical conditions. A potentially critical
factor not yet studied is heavy alcohol use or alcohol use disorder (AU/AUD). AU/AUD could increase the risk
for COVID-19 infection and poor prognosis through poor health behaviors, by direct effects of alcohol on the
immune system, or by indirect effects due to the greater prevalence of underlying medical conditions that predict
poor COVID-19 prognosis. Little is known about the relationship of AU/AUD to the likelihood of COVID-19
vaccination, infection, or poor prognosis, and if these relationships are modified by medical conditions (e.g.,
hypertension, obesity, diabetes), spatially-defined socioenvironmental or exposure variables (e.g., county
poverty or COVID-19 rates) or demographic characteristics (sex, age, race/ethnicity, poverty). To study this,
large databases are needed that include AU/AUD, demographic characteristics, spatial identifiers, diagnostic,
treatment and mortality information. Responding to PA-20-195 (and addressing issues in NOT-AA-20-011), we
will utilize the Veterans Administration (VA) Electronic Medical Record (EMR) system for this purpose. The VA
treats 6.3 million veterans a year. VA patients have high rates of COVID-19 vulnerability factors, e.g., male, older
age, chronic medical conditions. A VA Shared Data Resource identifies COVID-19 cases (now N=186,174, with
9,299 deaths). The many VA patients with ICD-10-CM AUD or positive alcohol (AUDIT-C) screens provide
extensive data on whether the likelihood of COVID-19 outcomes differ by AU/AUD status. Leveraging a research
infrastructure established in an existing project, we propose a 2-year study to comprehensively address the
relationship of AU/AUD to COVID-19 vaccination, infection and prognosis, and how these relationships are
affected by demographic, medical, spatial exposure characteristics. Aim1: Determine the relationship of AU/AUD
to COVID-19 vaccination, infection, and in those infected, poor prognosis (e.g., hospitalization, ICU treatment,
death). Aim 2: Determine if associations of AU/AUD with COVID-19 outcomes vary over time, medical conditions
(e.g., hypertension, obesity, diabetes), spatial exposures or demographic characteristics. In Year 01, we will
analyze EMR diagnostic, treatment, and vital status death data, using a 12-month lookback period to determine
AU/AUD and medical conditions that preceded COVID-19 outcome variables. In Year 02, we will incorporate
National Death Index data to examine causes of death, and expand information on veterans ≥age 65 with
Medicare data. Logistic regression will evaluate differences in COVID-19 outcomes by AU/AUD status. Among
those with COVID-19, survival models will determine if time to poor prognosis events differs by AU/AUD. Results
will fill major gaps in knowledge about the risks for and prognosis of COVID-19 among those with AU/AUD.
由SARS-CoV-2引起的冠状病毒病2019(新冠肺炎)是一种全球性的大流行。而大多数新冠肺炎
病例为轻度或中度,重症(~15%)需要住院,危重(~5%)需要加强治疗
护理,而且会发生许多死亡。男性、黑人和西班牙裔感染新冠肺炎的风险更高,而穷人
预后是通过年龄、种族/民族和既往潜在的医疗条件来预测的。一个潜在的关键
尚未研究的因素是酗酒或酒精使用障碍(AU/AUD)。澳元/澳元可能会增加风险
对于新冠肺炎感染和预后不良的不良健康行为,受酒精的直接影响。
免疫系统,或由间接影响,由于更普遍的潜在医疗条件,预测
新冠肺炎预后不良。关于澳元/澳元与新冠肺炎发病可能性的关系,我们知之甚少
接种疫苗、感染或预后不良,并且如果这些关系被医疗条件改变(例如,
高血压、肥胖、糖尿病)、空间定义的社会环境或暴露变量(例如,县
贫困或新冠肺炎比率)或人口特征(性别、年龄、种族/族裔、贫困)。为了研究这一点,
需要大型数据库,包括AU/AUD、人口特征、空间识别符、诊断、
治疗和死亡信息。响应PA-20-195(并解决NOT-AA-20-011中的问题),我们
将使用退伍军人管理局(退伍军人管理局)电子病历(EMR)系统来实现这一目的。退伍军人事务部
每年治疗630万名退伍军人。VA患者具有较高的新冠肺炎易感性因素,例如男性、年龄较大
年龄,慢性疾病。退伍军人事务部共享数据资源识别新冠肺炎案例(现在N=186,174,具有
9,299人死亡)。许多具有ICD-10-CM AUD或酒精阳性(AUD-C)筛查的VA患者提供
关于新冠肺炎结果的可能性是否因非盟/澳元状况而异的大量数据。利用一项研究
基础设施,我们建议进行为期两年的研究,以全面解决
AU/AUD与新冠肺炎接种、感染和预后的关系以及这些关系是如何
受人口统计、医疗、空间暴露特征的影响。目的1:确定AU/AUD的关系
对于新冠肺炎疫苗接种,感染,以及在那些感染的人中,预后较差(例如,住院,ICU治疗,
死亡)。目标2:确定AU/AUD与新冠肺炎预后的关联是否会随着时间、医疗条件的不同而变化
(例如,高血压、肥胖症、糖尿病)、空间暴露或人口特征。在公元01年,我们会
分析EMR诊断、治疗和生命状态死亡数据,使用12个月的回顾期间确定
Au/AUD和新冠肺炎结果变量之前的医疗条件。在公元02年,我们会把
国家死亡指数数据,以检查死因,并扩大关于65岁≥退伍军人的信息
医疗保险数据。Logistic回归将根据AU/AUD状态评估新冠肺炎结果的差异。其中
对于新冠肺炎患者,生存模型将决定预后不良事件发生的时间是否因AU/AUD而异。结果
将填补在AU/AUD患者中对新冠肺炎的风险和预后的主要知识空白。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEBORAH S HASIN其他文献
DEBORAH S HASIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEBORAH S HASIN', 18)}}的其他基金
COVID-19, heavy drinking and alcohol use disorders: a national study of Veterans Administration patients
COVID-19、酗酒和酒精使用障碍:一项针对退伍军人管理局患者的全国研究
- 批准号:
10596115 - 财政年份:2022
- 资助金额:
$ 25.57万 - 项目类别:
Scientific Conferences for The College on Problems of Drug Dependence (CPDD)
药物依赖问题学院科学会议(CPDD)
- 批准号:
10610865 - 财政年份:2021
- 资助金额:
$ 25.57万 - 项目类别:
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024
医用和娱乐大麻法对大麻、阿片类药物和精神药物的影响:2000 年至 2024 年退伍军人事务部患者的全国研究
- 批准号:
10393578 - 财政年份:2019
- 资助金额:
$ 25.57万 - 项目类别:
Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024
医用和娱乐大麻法对大麻、阿片类药物和精神药物的影响:2000 年至 2024 年退伍军人事务部患者的全国研究
- 批准号:
10612385 - 财政年份:2019
- 资助金额:
$ 25.57万 - 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints - Administrative Supplement
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点 - 行政补充
- 批准号:
10228425 - 财政年份:2016
- 资助金额:
$ 25.57万 - 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点
- 批准号:
9883624 - 财政年份:2016
- 资助金额:
$ 25.57万 - 项目类别:
Drinking levels (binge, volume) and alcohol consequences: using national data to identify clinical trial endpoints
饮酒水平(酗酒、饮酒量)和酒精后果:使用国家数据确定临床试验终点
- 批准号:
9440313 - 财政年份:2016
- 资助金额:
$ 25.57万 - 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
- 批准号:
9317400 - 财政年份:2014
- 资助金额:
$ 25.57万 - 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
- 批准号:
8731034 - 财政年份:2014
- 资助金额:
$ 25.57万 - 项目类别:
HealthCall: Enhancing brief intervention for HIV primary care alcohol dependence
HealthCall:加强对艾滋病毒初级保健酒精依赖的短期干预
- 批准号:
8932642 - 财政年份:2014
- 资助金额:
$ 25.57万 - 项目类别:
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 25.57万 - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
$ 25.57万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 25.57万 - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
$ 25.57万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 25.57万 - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
$ 25.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 25.57万 - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
$ 25.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
$ 25.57万 - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
$ 25.57万 - 项目类别:














{{item.name}}会员




